Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Mainfreight reports first-half margin squeeze
Markets

Mainfreight reports first-half margin squeeze

Ocean freight rates and trans-Pacific trade volumes are under pressure.

London’s AI reality check
Opinion

Peter Griffin: London’s AI reality check

Debate continues to rage about the extent to which we are in an AI bubble.

Election politics weigh on gentailer valuations
Markets

Election politics weigh on gentailer valuations

Political noise and manoeuvring are distorting the electricity market again.

NZ sharemarket dips ahead of Mainfreight, Infratil results
Markets Market Close

NZ sharemarket dips ahead of Mainfreight, Infratil results

The S&P/NZX 50 Index closed down 0.09% or 12.932 points to 13,604.55.

Tom Raynel 11 Nov 2025